A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Hosein, Peter J ^a   Macintyre, Jessica ^a   Kawamura, Carolina ^b   Maldonado, Jennifer C ^a   Ernani, Vinicius ^a   Loaiza Bonilla, Arturo ^a   Narayanan, Govindarajan ^a   Ribeiro, Afonso ^a   Portelance, Lorraine ^a   Merchan, Jaime R ^a   Levi, Joe U ^a   Rocha Lima, Caio M ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b HOSPITAL SÃO JOSÉ   (Brazil)

Author keywords

Neoadjuvant therapy; Pancreatic ductal carcinoma; Radiation therapy; Surgery

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT STENT; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CHOLANGITIS; CHOLEDOCHOJEJUNOSTOMY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SPLEEN INFECTION; SPLEEN INJURY; STENT; STOMACH PARESIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861465672     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-199     Document Type: Article

References (13)

1. American Cancer Society Cancer Facts & Figures 2011 2011, American Cancer Society, Atlanta, American Cancer Society.
2. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009, 16(7):1727-33. 10.1245/s10434-009-0408-6, 19396496.
3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7(4):e1000267. 10.1371/journal.pmed.1000267, 2857873, 20422030.
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-25. 10.1056/NEJMoa1011923, 21561347.
5. Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ. A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer: A Hoosier Oncology Group Study. Am J Clin Oncol 2011, 34(5):460-5. 10.1097/COC.0b013e3181e9c103, 20881474.
6. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 2011, 29(31):4105-4112. 10.1200/JCO.2011.34.8904, 21969502.
7. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25(3):326-31. 10.1200/JCO.2006.07.5663, 17235048.
8. Ychou M, Desseigne F, Guimbaud R, Ducreux M, Bouché O, Bécouarn Y, Adenis A, Montoto-Grillot C, Luporsi E, Conroy T. Randomized phase II trial comparing FOLFIRINOX vs gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. First results of the ACCORD 11 trial. J Clin Oncol 2007, 25(suppl 18):4516.
9. National Cancer I. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 2009, , .
10. Collett D. Modelling survival data in medical research 1994, Chapman & Hall, London.
11. Bendell JC, Britton S, Green MR, et al. Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC). J Clin Oncol 2011, 29(Suppl 4):286.
12. Kang SP, Saif MW. Three-drug combination regimen in pancreatic cancer treatment: are we there yet?. JOP 2011, 12:78-82.
13. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncol 2010, 12:8-9.